BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34063063)

  • 21. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer.
    Younes MN; Kim S; Yigitbasi OG; Mandal M; Jasser SA; Dakak Yazici Y; Schiff BA; El-Naggar A; Bekele BN; Mills GB; Myers JN
    Mol Cancer Ther; 2005 Aug; 4(8):1146-56. PubMed ID: 16093430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
    Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
    Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Galectin-1 and Its Inhibitors: Privileged Target for Cancer and HIV.
    Goud NS; Soukya PSL; Ghouse M; Komal D; Alvala R; Alvala M
    Mini Rev Med Chem; 2019; 19(16):1369-1378. PubMed ID: 30834831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?
    Lettini G; Pietrafesa M; Lepore S; Maddalena F; Crispo F; Sgambato A; Esposito F; Landriscina M
    Mol Cell Endocrinol; 2020 Feb; 502():110676. PubMed ID: 31812782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer.
    Williamson T; Mendes TB; Joe N; Cerutti JM; Riggins GJ
    Endocr Relat Cancer; 2020 Mar; 27(3):123-136. PubMed ID: 31846433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.
    Bauriaud-Mallet M; Vija-Racaru L; Brillouet S; Mallinger A; de Medina P; Rives A; Payre B; Poirot M; Courbon F; Silvente-Poirot S
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105390. PubMed ID: 31170473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Galectin-1 Promotes Metastasis in Gastric Cancer Through a Sphingosine-1-Phosphate Receptor 1-Dependent Mechanism.
    You X; Wang Y; Wu J; Liu Q; Chen D; Tang D; Wang D
    Cell Physiol Biochem; 2018; 51(1):11-30. PubMed ID: 30453284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.
    Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M
    Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
    Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
    Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
    [No Abstract]   [Full Text] [Related]  

  • 32. Selective activity of BS-RNase against anaplastic thyroid cancer.
    Kotchetkov R; Cinatl J; Krivtchik AA; Vogel JU; Matousek J; Pouckova P; Kornhuber B; Schwabe D; Cinatl J
    Anticancer Res; 2001; 21(2A):1035-42. PubMed ID: 11396137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galectin-8 induces endothelial hyperpermeability through the eNOS pathway involving S-nitrosylation-mediated adherens junction disassembly.
    Zamorano P; Koning T; Oyanadel C; Mardones GA; Ehrenfeld P; Boric MP; González A; Soza A; Sánchez FA
    Carcinogenesis; 2019 Apr; 40(2):313-323. PubMed ID: 30624618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS
    Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.
    Hua SC; Chang TC; Chen HR; Lu CH; Liu YW; Chen SH; Yu HI; Chang YP; Lee YR
    Pharm Res; 2012 Jul; 29(7):1990-2005. PubMed ID: 22477067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
    Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
    J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of anlotinib in thyroid cancer.
    Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
    Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.